0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long-acting Anti-HIV Drugs Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-12B18401
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Long acting Anti HIV Drugs Market Research Report 2024
BUY CHAPTERS

Global Long-acting Anti-HIV Drugs Market Research Report 2024

Code: QYRE-Auto-12B18401
Report
October 2024
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Long-acting Anti-HIV Drugs Market

Long-acting anti-HIV drugs are medications designed to provide sustained therapeutic effects with less frequent dosing compared to traditional antiretroviral therapies. These drugs, which include injectable formulations like cabotegravir and lenacapavir, allow for extended periods of protection or viral suppression, typically administered every month or every few months.
The global Long-acting Anti-HIV Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Long-acting Anti-HIV Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-acting Anti-HIV Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Long-acting Anti-HIV Drugs include ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Long-acting Anti-HIV Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Anti-HIV Drugs.
The Long-acting Anti-HIV Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Long-acting Anti-HIV Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Anti-HIV Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Long-acting Anti-HIV Drugs Market Report

Report Metric Details
Report Name Long-acting Anti-HIV Drugs Market
Segment by Type
  • Single Drug
  • Combination Preparation
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Long-acting Anti-HIV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Long-acting Anti-HIV Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Long-acting Anti-HIV Drugs Market report?

Ans: The main players in the Long-acting Anti-HIV Drugs Market are ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, Theratechnologies

What are the Application segmentation covered in the Long-acting Anti-HIV Drugs Market report?

Ans: The Applications covered in the Long-acting Anti-HIV Drugs Market report are HIV Prevention, HIV Treatment

What are the Type segmentation covered in the Long-acting Anti-HIV Drugs Market report?

Ans: The Types covered in the Long-acting Anti-HIV Drugs Market report are Single Drug, Combination Preparation

Recommended Reports

HIV & Antiretrovirals

Antiviral Drug Markets

Long-acting Formulations

1 Long-acting Anti-HIV Drugs Market Overview
1.1 Product Definition
1.2 Long-acting Anti-HIV Drugs by Type
1.2.1 Global Long-acting Anti-HIV Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Single Drug
1.2.3 Combination Preparation
1.3 Long-acting Anti-HIV Drugs by Application
1.3.1 Global Long-acting Anti-HIV Drugs Market Value by Application (2024-2030)
1.3.2 HIV Prevention
1.3.3 HIV Treatment
1.4 Global Long-acting Anti-HIV Drugs Market Size Estimates and Forecasts
1.4.1 Global Long-acting Anti-HIV Drugs Revenue 2019-2030
1.4.2 Global Long-acting Anti-HIV Drugs Sales 2019-2030
1.4.3 Global Long-acting Anti-HIV Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Long-acting Anti-HIV Drugs Market Competition by Manufacturers
2.1 Global Long-acting Anti-HIV Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Long-acting Anti-HIV Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Long-acting Anti-HIV Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Long-acting Anti-HIV Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Anti-HIV Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Anti-HIV Drugs, Product Type & Application
2.7 Global Key Manufacturers of Long-acting Anti-HIV Drugs, Date of Enter into This Industry
2.8 Global Long-acting Anti-HIV Drugs Market Competitive Situation and Trends
2.8.1 Global Long-acting Anti-HIV Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Long-acting Anti-HIV Drugs Players Market Share by Revenue
2.8.3 Global Long-acting Anti-HIV Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Long-acting Anti-HIV Drugs Market Scenario by Region
3.1 Global Long-acting Anti-HIV Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Long-acting Anti-HIV Drugs Sales by Region: 2019-2030
3.2.1 Global Long-acting Anti-HIV Drugs Sales by Region: 2019-2024
3.2.2 Global Long-acting Anti-HIV Drugs Sales by Region: 2025-2030
3.3 Global Long-acting Anti-HIV Drugs Revenue by Region: 2019-2030
3.3.1 Global Long-acting Anti-HIV Drugs Revenue by Region: 2019-2024
3.3.2 Global Long-acting Anti-HIV Drugs Revenue by Region: 2025-2030
3.4 North America Long-acting Anti-HIV Drugs Market Facts & Figures by Country
3.4.1 North America Long-acting Anti-HIV Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Long-acting Anti-HIV Drugs Sales by Country (2019-2030)
3.4.3 North America Long-acting Anti-HIV Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Anti-HIV Drugs Market Facts & Figures by Country
3.5.1 Europe Long-acting Anti-HIV Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Long-acting Anti-HIV Drugs Sales by Country (2019-2030)
3.5.3 Europe Long-acting Anti-HIV Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Anti-HIV Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Long-acting Anti-HIV Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Long-acting Anti-HIV Drugs Sales by Region (2019-2030)
3.6.3 Asia Pacific Long-acting Anti-HIV Drugs Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Anti-HIV Drugs Market Facts & Figures by Country
3.7.1 Latin America Long-acting Anti-HIV Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Long-acting Anti-HIV Drugs Sales by Country (2019-2030)
3.7.3 Latin America Long-acting Anti-HIV Drugs Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Long-acting Anti-HIV Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Anti-HIV Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Long-acting Anti-HIV Drugs Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Anti-HIV Drugs Sales by Type (2019-2030)
4.1.1 Global Long-acting Anti-HIV Drugs Sales by Type (2019-2024)
4.1.2 Global Long-acting Anti-HIV Drugs Sales by Type (2025-2030)
4.1.3 Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2019-2030)
4.2 Global Long-acting Anti-HIV Drugs Revenue by Type (2019-2030)
4.2.1 Global Long-acting Anti-HIV Drugs Revenue by Type (2019-2024)
4.2.2 Global Long-acting Anti-HIV Drugs Revenue by Type (2025-2030)
4.2.3 Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Long-acting Anti-HIV Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Long-acting Anti-HIV Drugs Sales by Application (2019-2030)
5.1.1 Global Long-acting Anti-HIV Drugs Sales by Application (2019-2024)
5.1.2 Global Long-acting Anti-HIV Drugs Sales by Application (2025-2030)
5.1.3 Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2019-2030)
5.2 Global Long-acting Anti-HIV Drugs Revenue by Application (2019-2030)
5.2.1 Global Long-acting Anti-HIV Drugs Revenue by Application (2019-2024)
5.2.2 Global Long-acting Anti-HIV Drugs Revenue by Application (2025-2030)
5.2.3 Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Long-acting Anti-HIV Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ViiV Healthcare
6.1.1 ViiV Healthcare Company Information
6.1.2 ViiV Healthcare Description and Business Overview
6.1.3 ViiV Healthcare Long-acting Anti-HIV Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ViiV Healthcare Long-acting Anti-HIV Drugs Product Portfolio
6.1.5 ViiV Healthcare Recent Developments/Updates
6.2 Janssen Pharmaceuticals
6.2.1 Janssen Pharmaceuticals Company Information
6.2.2 Janssen Pharmaceuticals Description and Business Overview
6.2.3 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product Portfolio
6.2.5 Janssen Pharmaceuticals Recent Developments/Updates
6.3 Gilead Sciences
6.3.1 Gilead Sciences Company Information
6.3.2 Gilead Sciences Description and Business Overview
6.3.3 Gilead Sciences Long-acting Anti-HIV Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Gilead Sciences Long-acting Anti-HIV Drugs Product Portfolio
6.3.5 Gilead Sciences Recent Developments/Updates
6.4 Theratechnologies
6.4.1 Theratechnologies Company Information
6.4.2 Theratechnologies Description and Business Overview
6.4.3 Theratechnologies Long-acting Anti-HIV Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Theratechnologies Long-acting Anti-HIV Drugs Product Portfolio
6.4.5 Theratechnologies Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Anti-HIV Drugs Industry Chain Analysis
7.2 Long-acting Anti-HIV Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Anti-HIV Drugs Production Mode & Process
7.4 Long-acting Anti-HIV Drugs Sales and Marketing
7.4.1 Long-acting Anti-HIV Drugs Sales Channels
7.4.2 Long-acting Anti-HIV Drugs Distributors
7.5 Long-acting Anti-HIV Drugs Customers
8 Long-acting Anti-HIV Drugs Market Dynamics
8.1 Long-acting Anti-HIV Drugs Industry Trends
8.2 Long-acting Anti-HIV Drugs Market Drivers
8.3 Long-acting Anti-HIV Drugs Market Challenges
8.4 Long-acting Anti-HIV Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Long-acting Anti-HIV Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Long-acting Anti-HIV Drugs Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Long-acting Anti-HIV Drugs Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Long-acting Anti-HIV Drugs Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Long-acting Anti-HIV Drugs Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Long-acting Anti-HIV Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Long-acting Anti-HIV Drugs Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Long-acting Anti-HIV Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Long-acting Anti-HIV Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Long-acting Anti-HIV Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Long-acting Anti-HIV Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Long-acting Anti-HIV Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Long-acting Anti-HIV Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Anti-HIV Drugs as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Long-acting Anti-HIV Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Long-acting Anti-HIV Drugs Sales by Region (2019-2024) & (K Units)
 Table 18. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2019-2024)
 Table 19. Global Long-acting Anti-HIV Drugs Sales by Region (2025-2030) & (K Units)
 Table 20. Global Long-acting Anti-HIV Drugs Sales Market Share by Region (2025-2030)
 Table 21. Global Long-acting Anti-HIV Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2019-2024)
 Table 23. Global Long-acting Anti-HIV Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Long-acting Anti-HIV Drugs Revenue Market Share by Region (2025-2030)
 Table 25. North America Long-acting Anti-HIV Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Long-acting Anti-HIV Drugs Sales by Country (2019-2024) & (K Units)
 Table 27. North America Long-acting Anti-HIV Drugs Sales by Country (2025-2030) & (K Units)
 Table 28. North America Long-acting Anti-HIV Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Long-acting Anti-HIV Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Long-acting Anti-HIV Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Long-acting Anti-HIV Drugs Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Long-acting Anti-HIV Drugs Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Long-acting Anti-HIV Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Long-acting Anti-HIV Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Long-acting Anti-HIV Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Long-acting Anti-HIV Drugs Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Long-acting Anti-HIV Drugs Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Long-acting Anti-HIV Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Long-acting Anti-HIV Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Long-acting Anti-HIV Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Long-acting Anti-HIV Drugs Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Long-acting Anti-HIV Drugs Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Long-acting Anti-HIV Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Long-acting Anti-HIV Drugs Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Long-acting Anti-HIV Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Long-acting Anti-HIV Drugs Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Long-acting Anti-HIV Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Long-acting Anti-HIV Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Long-acting Anti-HIV Drugs Sales (K Units) by Type (2019-2024)
 Table 51. Global Long-acting Anti-HIV Drugs Sales (K Units) by Type (2025-2030)
 Table 52. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2019-2024)
 Table 53. Global Long-acting Anti-HIV Drugs Sales Market Share by Type (2025-2030)
 Table 54. Global Long-acting Anti-HIV Drugs Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Long-acting Anti-HIV Drugs Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2019-2024)
 Table 57. Global Long-acting Anti-HIV Drugs Revenue Market Share by Type (2025-2030)
 Table 58. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Long-acting Anti-HIV Drugs Sales (K Units) by Application (2019-2024)
 Table 61. Global Long-acting Anti-HIV Drugs Sales (K Units) by Application (2025-2030)
 Table 62. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2019-2024)
 Table 63. Global Long-acting Anti-HIV Drugs Sales Market Share by Application (2025-2030)
 Table 64. Global Long-acting Anti-HIV Drugs Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Long-acting Anti-HIV Drugs Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2019-2024)
 Table 67. Global Long-acting Anti-HIV Drugs Revenue Market Share by Application (2025-2030)
 Table 68. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Application (2025-2030)
 Table 70. ViiV Healthcare Company Information
 Table 71. ViiV Healthcare Description and Business Overview
 Table 72. ViiV Healthcare Long-acting Anti-HIV Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. ViiV Healthcare Long-acting Anti-HIV Drugs Product
 Table 74. ViiV Healthcare Recent Developments/Updates
 Table 75. Janssen Pharmaceuticals Company Information
 Table 76. Janssen Pharmaceuticals Description and Business Overview
 Table 77. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Janssen Pharmaceuticals Long-acting Anti-HIV Drugs Product
 Table 79. Janssen Pharmaceuticals Recent Developments/Updates
 Table 80. Gilead Sciences Company Information
 Table 81. Gilead Sciences Description and Business Overview
 Table 82. Gilead Sciences Long-acting Anti-HIV Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Gilead Sciences Long-acting Anti-HIV Drugs Product
 Table 84. Gilead Sciences Recent Developments/Updates
 Table 85. Theratechnologies Company Information
 Table 86. Theratechnologies Description and Business Overview
 Table 87. Theratechnologies Long-acting Anti-HIV Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Theratechnologies Long-acting Anti-HIV Drugs Product
 Table 89. Theratechnologies Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Long-acting Anti-HIV Drugs Distributors List
 Table 93. Long-acting Anti-HIV Drugs Customers List
 Table 94. Long-acting Anti-HIV Drugs Market Trends
 Table 95. Long-acting Anti-HIV Drugs Market Drivers
 Table 96. Long-acting Anti-HIV Drugs Market Challenges
 Table 97. Long-acting Anti-HIV Drugs Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Long-acting Anti-HIV Drugs
 Figure 2. Global Long-acting Anti-HIV Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Long-acting Anti-HIV Drugs Market Share by Type: 2023 & 2030
 Figure 4. Single Drug Product Picture
 Figure 5. Combination Preparation Product Picture
 Figure 6. Global Long-acting Anti-HIV Drugs Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Long-acting Anti-HIV Drugs Market Share by Application: 2023 & 2030
 Figure 8. HIV Prevention
 Figure 9. HIV Treatment
 Figure 10. Global Long-acting Anti-HIV Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 11. Global Long-acting Anti-HIV Drugs Market Size (2019-2030) & (US$ Million)
 Figure 12. Global Long-acting Anti-HIV Drugs Sales (2019-2030) & (K Units)
 Figure 13. Global Long-acting Anti-HIV Drugs Average Price (US$/Unit) & (2019-2030)
 Figure 14. Long-acting Anti-HIV Drugs Report Years Considered
 Figure 15. Long-acting Anti-HIV Drugs Sales Share by Manufacturers in 2023
 Figure 16. Global Long-acting Anti-HIV Drugs Revenue Share by Manufacturers in 2023
 Figure 17. Global 5 and 10 Largest Long-acting Anti-HIV Drugs Players: Market Share by Revenue in Long-acting Anti-HIV Drugs in 2023
 Figure 18. Long-acting Anti-HIV Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 19. Global Long-acting Anti-HIV Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 20. North America Long-acting Anti-HIV Drugs Sales Market Share by Country (2019-2030)
 Figure 21. North America Long-acting Anti-HIV Drugs Revenue Market Share by Country (2019-2030)
 Figure 22. United States Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 23. Canada Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Europe Long-acting Anti-HIV Drugs Sales Market Share by Country (2019-2030)
 Figure 25. Europe Long-acting Anti-HIV Drugs Revenue Market Share by Country (2019-2030)
 Figure 26. Germany Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. France Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. U.K. Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. Italy Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Russia Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Asia Pacific Long-acting Anti-HIV Drugs Sales Market Share by Region (2019-2030)
 Figure 32. Asia Pacific Long-acting Anti-HIV Drugs Revenue Market Share by Region (2019-2030)
 Figure 33. China Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Japan Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. South Korea Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. India Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Australia Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. China Taiwan Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Southeast Asia Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Latin America Long-acting Anti-HIV Drugs Sales Market Share by Country (2019-2030)
 Figure 41. Mexico Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Brazil Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Argentina Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Colombia Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Middle East and Africa Long-acting Anti-HIV Drugs Sales Market Share by Country (2019-2030)
 Figure 46. Middle East and Africa Long-acting Anti-HIV Drugs Revenue Market Share by Country (2019-2030)
 Figure 47. Turkey Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Saudi Arabia Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. UAE Long-acting Anti-HIV Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Global Sales Market Share of Long-acting Anti-HIV Drugs by Type (2019-2030)
 Figure 51. Global Revenue Market Share of Long-acting Anti-HIV Drugs by Type (2019-2030)
 Figure 52. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Type (2019-2030)
 Figure 53. Global Sales Market Share of Long-acting Anti-HIV Drugs by Application (2019-2030)
 Figure 54. Global Revenue Market Share of Long-acting Anti-HIV Drugs by Application (2019-2030)
 Figure 55. Global Long-acting Anti-HIV Drugs Price (US$/Unit) by Application (2019-2030)
 Figure 56. Long-acting Anti-HIV Drugs Value Chain
 Figure 57. Long-acting Anti-HIV Drugs Production Process
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona